Efficacy and Safety of Efdamrofusp Alfa with Personalized Dosing Intervals in Neovascular Age-Related Macular Degeneration: A Phase II Trial
采用个性化给药间隔的 Efdamrofusp Alfa 治疗新生血管性年龄相关性黄斑变性的疗效和安全性:一项 II 期试验
期刊:Ophthalmology Science
影响因子:4.600
doi:10.1016/j.xops.2025.100913
Li, Tong; Yang, Shiqi; Liu, Qinghuai; Song, Yanping; Tong, Jianping; Wei, Wenbin; Chen, Weiqi; Dai, Hong; Wang, Wei; Wu, Miaoqin; Zhou, Guohong; Xiao, Xuan; Zhang, Jinglin; Zhu, Rongrong; Li, Haoyu; Wang, Yafang; Chen, Xiaoyu; Lu, Shujie; Du, Haiwei; Han-Zhang, Han; Hao, Jilong; Li, Chaopeng; Wen, Ying; Zhang, Jie; Sun, Junran; Jia, Huixun; Sun, Xiaodong